[go: up one dir, main page]

HRP20000327A2 - Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor - Google Patents

Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor Download PDF

Info

Publication number
HRP20000327A2
HRP20000327A2 HR20000327A HRP20000327A HRP20000327A2 HR P20000327 A2 HRP20000327 A2 HR P20000327A2 HR 20000327 A HR20000327 A HR 20000327A HR P20000327 A HRP20000327 A HR P20000327A HR P20000327 A2 HRP20000327 A2 HR P20000327A2
Authority
HR
Croatia
Prior art keywords
chloro
indole
amide
carboxylic acid
oxo
Prior art date
Application number
HR20000327A
Other languages
English (en)
Croatian (hr)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP20000327A2 publication Critical patent/HRP20000327A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Noise Elimination (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superheterodyne Receivers (AREA)
HR20000327A 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor HRP20000327A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
HRP20000327A2 true HRP20000327A2 (en) 2001-02-28

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000327A HRP20000327A2 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Country Status (38)

Country Link
EP (1) EP1032424B9 (pt)
JP (1) JP2002504478A (pt)
KR (2) KR20010032304A (pt)
CN (1) CN1279617A (pt)
AP (1) AP911A (pt)
AR (1) AR016423A1 (pt)
AT (1) ATE205403T1 (pt)
AU (1) AU733304B2 (pt)
BG (1) BG104435A (pt)
BR (1) BR9814698A (pt)
CA (1) CA2310069A1 (pt)
DE (1) DE69801680T2 (pt)
DK (1) DK1032424T3 (pt)
DZ (1) DZ2656A1 (pt)
EA (1) EA002365B1 (pt)
ES (1) ES2161548T3 (pt)
GR (1) GR3037071T3 (pt)
GT (1) GT199800166A (pt)
HR (1) HRP20000327A2 (pt)
HU (1) HUP0100272A3 (pt)
ID (1) ID24524A (pt)
IL (1) IL135713A0 (pt)
IS (1) IS5453A (pt)
MA (1) MA26568A1 (pt)
NO (1) NO20002164L (pt)
OA (1) OA11379A (pt)
PA (1) PA8462301A1 (pt)
PE (1) PE135399A1 (pt)
PL (1) PL340643A1 (pt)
PT (1) PT1032424E (pt)
SK (1) SK7222000A3 (pt)
TN (1) TNSN98211A1 (pt)
TR (1) TR200001451T2 (pt)
UA (1) UA57811C2 (pt)
UY (1) UY25258A1 (pt)
WO (1) WO1999026659A1 (pt)
YU (1) YU30700A (pt)
ZA (1) ZA9810636B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
PT1741445E (pt) 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1997533B8 (en) 2003-11-12 2014-10-29 Sino-Med International Alliance, Inc. Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
HRP20140091T4 (hr) 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
EP2144902B1 (en) 2007-05-04 2012-05-16 Bristol-Myers Squibb Company [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
JP2010526146A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
CA2693444A1 (en) 2007-07-17 2009-01-22 Bristol-Myers Squibb Company Method for modulating gpr119 g protein-coupled receptor and selected compounds
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
HUE026715T2 (en) 2011-01-20 2016-07-28 Bionevia Pharmaceuticals Inc Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
KR102513342B1 (ko) 2016-07-22 2023-03-22 브리스톨-마이어스 스큅 컴퍼니 글루코키나제 활성화제 및 그의 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.

Also Published As

Publication number Publication date
KR20010032300A (ko) 2001-04-16
HUP0100272A3 (en) 2002-11-28
KR100661214B1 (ko) 2006-12-26
PL340643A1 (en) 2001-02-12
EP1032424A1 (en) 2000-09-06
GR3037071T3 (en) 2002-01-31
DK1032424T3 (da) 2001-11-19
ATE205403T1 (de) 2001-09-15
ES2161548T3 (es) 2001-12-01
AP911A (en) 2000-12-07
DE69801680D1 (de) 2001-10-18
SK7222000A3 (en) 2001-09-11
YU30700A (sh) 2002-12-10
ZA9810636B (en) 2000-05-22
BR9814698A (pt) 2000-10-03
DZ2656A1 (fr) 2003-03-22
EA200000433A1 (ru) 2000-12-25
AR016423A1 (es) 2001-07-04
PA8462301A1 (es) 2000-05-24
WO1999026659A1 (en) 1999-06-03
HUP0100272A2 (hu) 2001-06-28
NO20002164D0 (no) 2000-04-27
TNSN98211A1 (fr) 2005-03-15
AU9555898A (en) 1999-06-15
UA57811C2 (uk) 2003-07-15
TR200001451T2 (tr) 2002-06-21
AP9801401A0 (en) 1998-12-31
ID24524A (id) 2000-07-20
NO20002164L (no) 2000-07-19
IS5453A (is) 2000-04-14
DE69801680T2 (de) 2002-02-07
PE135399A1 (es) 2000-01-15
JP2002504478A (ja) 2002-02-12
IL135713A0 (en) 2001-05-20
CA2310069A1 (en) 1999-06-03
CN1279617A (zh) 2001-01-10
MA26568A1 (fr) 2004-12-20
OA11379A (en) 2004-01-28
BG104435A (bg) 2001-01-31
AU733304B2 (en) 2001-05-10
UY25258A1 (es) 2000-12-29
EA002365B1 (ru) 2002-04-25
GT199800166A (es) 2000-04-19
KR20010032304A (ko) 2001-04-16
PT1032424E (pt) 2001-12-28
EP1032424B1 (en) 2001-09-12
EP1032424B9 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
HRP20000327A2 (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
AU717547B2 (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
KR101098584B1 (ko) 세포괴사 저해제로서의 인돌 화합물
JP4854511B2 (ja) 糖尿病治療剤
HRP960266A2 (en) Substituted n-(indole-2-carbonyl-)amides and derivatives as antidiabetic agents
CA2279732A1 (en) Method of inhibition of human glycogen phosphorylase
JP2010168387A (ja) マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
US6277877B1 (en) Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
HUP0100321A2 (en) Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
JP2018509474A (ja) インダン酢酸誘導体を用いる肝疾患の治療方法
JPWO2017170826A1 (ja) グルカゴン様ペプチド−１受容体作用増強活性を有する化合物
US20160279079A1 (en) Compositions and methods for treating bone diseases
MXPA00005025A (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
RO116963B1 (ro) Derivaţi de n-(indol-2-carbonil)-beta-alaninamide substituite, compoziţii farmaceutice şi metodă de tratament
HK1048265A1 (zh) 联合疗法
CZ20001837A3 (cs) Kombinace inhibitoru aldosa reduktasy a inhibitoru glykogen fosforylasy
JP2003518493A (ja) 新規治療方法
HK40102350A (zh) 用於治疗肾脏疾患的化合物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20021102

Year of fee payment: 5

OBST Application withdrawn